The American Journal of Psychiatry
Journal Home Search Current Issue Past Issues Subscribe All APPI Journals Help Contact Us
 
Am J Psychiatry 2009; 166:460-466
(published online February 17, 2009; doi: 10.1176/appi.ajp.2008.08040597)
© 2009 American Psychiatric Association
Quicksearch
Advanced Search
Or Search All APPI Journals
This Article
* Full Text
* Full Text (PDF)
* Alert me when this article is cited
* Alert me if a correction is posted
* Citation Map
Services
* Email this article to a Colleague
* Similar articles in this journal
* Similar articles in PubMed
* Alert me to new issues of the journal
* Add to My Articles & Searches
* Download to citation manager
* reprints & permissions
Citing Articles
* Citing Articles via Google Scholar
Google Scholar
* Articles by Bolbecker, A. R.
* Articles by Shekhar, A. S.
* Search for Related Content
PubMed
* PubMed Citation
* Articles by Bolbecker, A. R.
* Articles by Shekhar, A. S.
Related Collections
* Schizophrenia Spectrum Disorders

Secretin Effects on Cerebellar-Dependent Motor Learning in Schizophrenia

Amanda R. Bolbecker, Ph.D., William P. Hetrick, Ph.D., Jason K. Johannesen, Ph.D., Brian F. O’Donnell, Ph.D., Joseph E. Steinmetz, Ph.D., and Anantha S. Shekhar, M.D., Ph.D.

OBJECTIVE: Pervasive cognitive deficits in schizophrenia are a major cause of disability among individuals with the disorder. One such deficit is the loss of effective associative learning, which is readily assessed via eye-blink conditioning procedures. The authors examined the efficacy of secretin, a hormonal agonist for the prototype group B G-protein-coupled receptors, in ameliorating eye-blink conditioning deficits in schizophrenia patients. METHOD: Immediately following a pretreatment delay eye-blink conditioning recording session, 25 individuals with schizophrenia received either secretin (RG1068; 20 µg/kg [N=15]) or a saline placebo (20 µg/kg [N=10]) subcutaneously in a double-blind fashion. Comparison groups were formed by yoking pairs of subjects on the basis of performance during the pretreatment baseline eye-blink conditioning recording session, and thus 20 subjects underwent further analysis. Secretin was selected because eye-blink conditioning depends on the release of Purkinje cell inhibition on deep nuclei of the cerebellum and recent findings indicate that secretin is endogenously released in the cerebellum, where it acts as a retrograde messenger and neuromodulator on basket and Purkinje cells. RESULTS: Eye-blink conditioning was significantly improved at 2 and 24 hours after secretin administration but not after treatment with placebo. These results are consistent with evidence of intracellular signaling abnormalities in the pathophysiology of schizophrenia and indicate a possible role for secretin in modulating cerebellar-mediated classically conditioned learning. CONCLUSION: If cerebellar abnormalities in individuals with schizophrenia are associated with fundamental mechanisms and symptoms of the disorder, as suggested by the cognitive dysmetria model, then cerebellar-targeted treatments may provide a novel approach to treatment for schizophrenia.







Get information about faster international access.

Privacy Policy

Copyright © 2009 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us

American Psychiatric Publishing, Inc. American Psychiatric Association
1000 Wilson Boulevard, Suite 1825, Arlington, VA 22209-3901 * 800-368-5777 * appi at psych.org